Rugonersen - Oak Hill Bio
Alternative Names: OHB-724; RG 6091; RO 7248824; UBE3A-LNALatest Information Update: 28 Jun 2026
At a glance
- Originator Roche
- Class Antisense oligonucleotides
- Mechanism of Action Gene silencing; UBE3A protein expression stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Angelman syndrome
Most Recent Events
- 28 Jun 2026 No recent reports of development identified for phase-I development in Angelman-syndrome(In children, In infants) in Italy (Intrathecal, Injection)
- 28 Jun 2026 No recent reports of development identified for phase-I development in Angelman-syndrome(In children, In infants) in Netherlands (Intrathecal, Injection)
- 28 Jun 2026 No recent reports of development identified for phase-I development in Angelman-syndrome(In children, In infants) in Spain (Intrathecal, Injection)